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Summary 
Acute pancreatitis (AP), a human disease in which the pancreas digests itself, has 
substantial mortality with no specific therapy. The major causes of AP are alcohol 
abuse and gallstone complications, but it also occurs as an important side effect of 
the standard Asparaginase-based therapy for childhood acute lymphoblastic 
leukaemia. Previous investigations into the mechanisms underlying pancreatic acinar 
cell death induced by alcohol metabolites, bile acids or Asparaginase indicated that 
loss of intracellular ATP generation is a significant factor. In isolated mouse 
pancreatic acinar cells or cell clusters, we now report that removal of extracellular 
glucose had little effect on this ATP loss, suggesting that glucose metabolism was 
severely inhibited under these conditions. Surprisingly, we show that replacing 
glucose with galactose prevented or markedly reduced the loss of ATP and any 
subsequent necrosis. Addition of pyruvate had a similar protective effect. We also 
studied the effect of galactose in vivo in mouse models of AP induced either by a 
combination of fatty acids and ethanol or Asparaginase. In both cases, galactose 
markedly reduced acinar necrosis and inflammation. Based on these data we suggest 
that galactose feeding may be used to protect against AP. 
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Introduction 
Acute pancreatitis (AP) is an inflammatory disease that originates in the exocrine pancreas, 
where inactive pancreatic pro-enzymes become prematurely activated inside the pancreatic 
acinar cells (PACs), digesting the pancreas and its surroundings (1,2). The main causes of 
AP are excessive alcohol and fatty food intake and gallstone disease, comprising about 80% 
of all cases (3). Stimulation of PACs with alcohol metabolites or bile acids leads to aberrant 
calcium signalling due to excessive release from intracellular stores followed by activation of 
massive Ca2+ entry through store operated Ca2+ release activated Ca2+ (CRAC) channels 
causing intracellular Ca2+ overload (2,4,5). 
Another cause of AP is the L-Asparaginase treatment of acute lymphoblastic leukaemia (ALL) 
(6,7). According to Cancer Research UK, there were 760 new cases of ALL diagnosed in the 
UK in 2014. The incidence rates for ALL are highest in children aged 0-4 (2012-2014). Anti-
leukemic drugs based on L-Asparaginase are currently used in the clinic as an effective 
treatment of childhood ALL (8-12). However, in up to 10% of the cases the Asparaginase 
treatment has to be truncated due to development of AP, a serious and incurable illness 
(6,7,13-17). Although Asparaginase-based drugs have been used in the clinic for many years 
(8), the mechanism of this side effect has not been well explored and understood.  
We have recently made progress in understanding the mechanism of Asparaginase-induced 
acute pancreatitis (AAP) (18). Our key findings include the activation of protease activated 
receptor 2 (PAR2) as well as calcium overload and loss of ATP in PACs. These findings 
provide the first mechanistic insight into the process by which Asparaginase treatment of ALL 
may cause AAP. The Asparaginase effect on cancer cells relies on the depletion of 
asparagine, which the malignant cells cannot produce by themselves, as opposed to normal 
cells (19,20). However, the AP inducing side effects of Asparaginase do not depend on 
presence or absence of asparagine (18). In contrast, the AP-inducing side effect of 
Asparaginase is caused by the activation of a signal transduction mechanism involving PAR2 
which, via a number of steps, causes cytosolic Ca2+ overloading and reduction in the 
intracellular ATP level. The reduction of energy supply inhibits both the plasma membrane 
Ca2+ ATPase (PMCA) and the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) (21-23). 
We have recently shown that restoration of energy supply, by the addition of pyruvate, 
provides an astonishingly high degree of protection against pancreatic necrosis (18).  
We have now analysed the role of glycolysis in AP in more detail, in vivo and in vitro, and 
specifically compared the effects of pyruvate, galactose (24) and glucose on the functional 
and morphological features of AP and AAP. Based on these data, we propose a simple and 
promising way to rescue intracellular ATP levels in AP and AAP patients. 
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Results  
ATP loss is the common hallmark of AP 
It has been established previously that ATP loss in AP is a critical part of the pathological 
mechanism in PACs, irrespective of whether it has been initiated by alcohol metabolites or 
bile acids (BA) (1,22,25). As previously described (18) we have assessed intracellular 
changes in ATP concentration by using Magnesium Green (MgGreen) fluorescence 
measurements. As most of the intracellular ATP will be in the form of Mg-ATP, a reduction of 
the ATP concentration will increase the fluorescence intensity of MgGreen due to the 
increase in free Mg2+ concentration. We have studied the effect of Asparaginase in PACs 
and found that 30 min of exposure to this agent caused a 45.8+4.8% loss of ATP (Fig.1A).  
The ATP reduction induced by Asparaginase was very similar to that elicited by exposure to 
the non-oxidative alcohol metabolite palmitoleic acid ethyl ester (POAEE, 40.9+4.9%), and 
palmitoleic acid (POA, 66.9+4.9%) (26) or a bile acid mixture (BA, 51.6+3.3%) (Fig.1A), 
while removal of glucose for 30 min led to a substantially smaller reduction (15.5+0.95%). 
Interestingly, removal of glucose did not significantly increase ATP depletion induced by 
POA or BA, but partially increased ATP depletion induced by BA (Fig.1A).  
Since the majority of cellular ATP is produced by glucose metabolism, we have compared 
the effect of a glucose free-medium on necrosis to that induced by Asparaginase, POAEE, 
POA, or BA (Fig.1B). In these experiments, lasting 2 hours we found that removal of glucose 
produced a comparable level of necrosis to all other pathological agents (14.8+0.5%, 
p<0.0001), but did not significantly exacerbate the effects of Asparaginase (p>0.059), 
marginally increased POA-elicited necrosis (from 20.0+0.3% to 22.2+0.7%, p<0.01) (Fig.1B), 
and somewhat increased BA-induced necrosis (from 18.3+1.1% to 29.4+2.5%, p<0.008). 
The fact that removal of glucose did not further increase the extent of necrosis induced by 
Asparaginase or POA may suggest that glucose metabolism is already so strongly inhibited 
by these two agents that removal of external glucose has practically no additional effect.  
 
Pyruvate and galactose rescue bile- and alcohol metabolite- induced pathology 
In our previous study into the mechanism by which Asparaginase evokes pathological 
changes in isolated PACs (18), we have shown that inclusion of pyruvate in the bathing 
solution provided remarkable protection against necrosis. We furthermore demonstrated that 
the reduction in the intracellular ATP level caused by Asparaginase was significantly 
diminished when pyruvate was present (18). In addition to pyruvate we decided to test 
galactose for its effectiveness in protection against alcohol- and bile-induced pancreatic 
pathologies. Galactose very significantly reduced the ATP loss caused by the alcohol 
metabolites POAEE (Fig.2A,B) and POA (Fig.2D,E) and also essentially prevented the 
necrosis induced by these agents (Fig.2C,F). Pyruvate had a very similar effect (Fig.2F). A 
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similar protective effect of pyruvate was also found in the case of bile-related pathology. 
Pyruvate substantially reduced the ATP loss elicited by BA (Fig.2G,H) and both pyruvate 
and galactose almost entirely eliminated the BA-induced necrosis (Fig.2I).  
 
Pyruvate and galactose protect against Asparaginase-induced necrosis 
The ability of galactose to protect against necrosis induced by POAEE, POA or BA 
(Fig.2C,F,I) has prompted us to also test the effect of galactose on Asparaginase-induced 
pathology (18). Both, pyruvate and galactose, at either 1 mM (Fig.3A,B) or 10 mM (Fig 3C) 
had similar protective effects against Asparaginase-induced necrosis in PACs. Interestingly, 
the presence or absence of glucose made no difference to the extent of the necrosis 
(Fig.1B). These data suggest that glucose metabolism is severely affected by Asparaginase, 
but that energy supply can be rescued by galactose or pyruvate joining the glycolysis cycle. 
 
Galactose and pyruvate, but not glucose, rescue the Asparaginase-induced pathology 
  
With regards to the primary action of Asparaginase on PACs, we have previously shown that 
this agent evokes a sustained elevation of the cytosolic Ca2+ concentration ([Ca2+]i) due to 
interaction with PAR2 (18). Fig.4A-B show that both pyruvate and galactose very markedly 
reduced the Asparaginase-elicited [Ca2+]i rise. In control experiments pyruvate and galactose 
did not change the frequency of Ca2+ oscillations induced by either CCK (p>0.3, n=11 and 
p>0.9, n=11 respectively) or Asparaginase (p>0.1, n=33 and p>0.7, n=17, respectively). 
There was also no significant difference with regard to the amplitude of spikes induced by 
CCK (p>0.8, n=157 and p>0.8, n=46 respectively). The amplitude of Asparaginase-induced 
oscillations was reduced by 20%(p<0.0001, n=39) in the presence of pyruvate and by 15% 
(p<0.02, n=26) in the presence of galactose. These relatively minor effects are probably due 
to the increase in the cytoplasmic ATP level and, therefore, Ca2+ uptake after release. 
Previously we have shown that Asparaginase inhibits Ca2+ extrusion from PACs, most likely 
due to the reduced availability of ATP (18). 
Although the Asparaginase-elicited sustained rise in [Ca2+]i depends on increased Ca2+ entry 
(18), this could be compensated by an increase in the rate of active Ca2+ extrusion, if an 
adequate supply of ATP is available. It would seem possible that ATP supply is enhanced in 
the presence of pyruvate or galactose and that this could be the mechanism by which the toxic 
[Ca2+]i rise is inhibited. We therefore tested this hypothesis by assessing changes in the 
intracellular ATP concentration (Fig.4C,D) as well as changes in NADH and FAD 
(Supplemental SFig.1A,B).  
Asparaginase induced a substantial intracellular ATP loss (Fig.4C-E), in line with reduction of 
NADH (SFig.1A). Replacement of glucose with pyruvate or galactose (both 10 mM, Fig.4C,D) 
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or adding 1mM pyruvate or galactose (Fig.4E) markedly reduced the Asparaginase-induced 
ATP loss. Replacing glucose with pyruvate or galactose was very effective in protecting 
against ATP loss and we therefore compared our results in the presence and absence of 
glucose and pyruvate (Fig.4F-H). The ATP loss was substantially higher in the absence of 
pyruvate (red and orange traces) regardless of the presence or absence of glucose. 
Comparison of the ‘areas under the curve’ shows that 1mM pyruvate (blue and green traces) 
significantly reduced the ATP loss (Fig.4G), whereas the presence of 10 mM glucose did not 
(p>0.05). Comparison of the amplitudes (Fig.4H) showed very similar results, namely that the 
glucose-independent ATP loss was markedly reduced by 1 mM pyruvate. Asparaginase also 
affected the mitochondrial potential (SFig.2A-F) and the mitochondrial Ca2+ levels (SFig.3A-
F), but, pyruvate and galactose restored these parameters to near control levels.  
 
Pyruvate and galactose increase intracellular ATP levels  
 
All the three AP-inducing factors that we tested substantially inhibited ATP production and 
both Asparaginase and POA severely inhibited glucose metabolism. Galactose can enter the 
glycolysis cycle, skipping its first step and does not depend on hexokinase activity. Our data 
may therefore indicate that glucokinase/hexokinase activity is inhibited during the induction 
of AP. Both galactose and pyruvate provide an additional source of ATP and increase 
intracellular ATP levels (Fig.5A,B).  
The glucose analogue 2-Deoxy-D-glucose (2-DG) (27), which inhibits glycolysis via its 
indirect actions on hexokinase, induced a substantial ATP loss (Fig.5C), necrosis (Fig.5D) 
and [Ca2+]i elevations (Fig.5E,F), very similar effects to those induced by Asparaginase 
(Fig.4A-D and Fig.3B and Fig.5D). Pyruvate significantly reduced the 2-DG-induced 
sustained [Ca2+]i elevation (Fig 5E,F). The rescue effects of galactose were completely 
blocked by the glucose transport inhibitor phloretin (SFig.1C), suggesting that only 
hexokinase inhibition could explain the ATP depletion observed in AP.  
 
Hexokinase activity is inhibited in vitro by POA and BA 
 
To test our hypothesis that AP-inducing agents cause intracellular ATP loss by reducing 
hexokinase activity, we measured in vitro the activities of the three major human 
hexokinases present in the pancreas (28,29). We found that POA markedly reduced the 
activity of hexokinase 1 and partially reduced hexokinase 2 activity (Fig.6AB). Whereas POA 
had no effect on glucokinase (HK4), BA markedly reduced HK4 activity (Fig.6C), but had no 
effect on HK1 and 2 (Fig.6A-C). In control experiments we found that the only other enzyme 
present in the cuvette (glucose-6-phosphate dehydrogenase) was not affected by either 
POA or BA (p>0.6 and p>0.4 respectively, as compared with control n=5). We also 
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measured the activity of hexokinase 3, that has relatively low abundance in most tissues 
except myeloid cells, but we did not find any significant inhibition by either POA or BA as 
compared to control (n=5). POAEE partially, but significantly, inhibited hexokinase 1 
(p<0.004, n=3) but did not affect other hexokinases. The Western blot (Fig.6D) shows that 
HK1, HK2 and HK4 are all present in mouse PACs. We conclude that the pathological 
hexokinase inhibition, particularly of HK1 by POA and HK4 by BA, play the key role in the 
ATP depletion that is such a significant feature of AP. In line with these data, a relatively high 
concentration of insulin (100 nM), stimulated hexokinases and rescued Asparaginase-, POA- 
and BA-induced necrosis (SFig.1D). An increased glucose concentration (30 mM) only 
stimulated glucokinase and, therefore, rescued Asparaginase- and POA- but not BA-induced 
necrosis (SFig.1D). 
 
Galactose administration protects from alcohol-induced AP in vivo 
To test whether our findings could lead to a rational treatment of AP, we focussed our 
attention specifically on the possibility that galactose might be helpful, as this sugar has 
already been included as part of human trials for the treatment of glycogen storage disease 
type 1b (Fabry’s disease), nephrotic syndrome, congenital disorders of glycosylation and has 
not been shown to have any negative effects (30-33). Galactose, an essential component of 
human breast milk (up to 70 mM during the first month (34)), is quite stable in solution, 
relatively slowly metabolised as compared to pyruvate and has been administered both by 
intraperitoneal injections and feeding (drink) protocols (35-37). We tested the protective 
effect of galactose in vivo, in a realistic mouse model in which AP was induced by a mixture 
of POA and alcohol (FAEE-AP (38)). As shown in Fig.7A-E, galactose significantly improved 
the histology score (Fig.7E) and reduced the degrees of edema (Fig.7B), inflammation 
(Fig.7C) and necrosis (Fig.7D). Galactose also rescued the alcohol-induced increase in 
amylase activity (SFig.4A), interleukin 6 (IL6), SFig.4B) and intracellular trypsin (SFig.5A-H). 
Control glucose feeding did not affect amylase activity (SFig.4A) but was able to partially 
restore IL6 levels.  The weight loss, typically seen in AP was partially prevented by galactose 
but not glucose (SFig.4C,D). Overall, galactose had a remarkable protective effect against 
experimental alcohol-related AP.  
 
Galactose administration inhibits Asparaginase-induced AP in vivo 
 
The experiments shown in Fig.3B,C indicate that it might be possible to use galactose to 
boost energy production in vivo to counteract the toxic effects of Asparaginase. We have 
therefore developed a mouse model of Asparaginase-induced AP, using an approach similar 
to that developed for studying AP induced by alcohol metabolites, bile and caerulein (38).  
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Asparaginase injections resulted in significantly increased histology scores, high degrees of 
edema, inflammation and necrosis (Fig.8A-E) that were similar to those reported for other 
AP models (38). As seen in Fig.8A-E, galactose significantly reduced the histology score and 
the degrees of edema, inflammation and necrosis towards much lower values in both 
feeding, and combination of injection and feeding, protocols with similar efficacy. The weight 
loss typical for AP was also partially reduced (SFig.4D). Therefore, we conclude that 
galactose could become a new effective supplemental treatment for AAP.  
 
Discussion 
It is well established that the initial stages of AP are characterised by intracellular Ca2+ 
overload, causing inadequate function of the mitochondria leading to reduction of ATP 
production, premature intracellular activation of digestive enzymes and cell death mainly by 
necrosis (1,2). 
Our new data reveal that AP-inducing agents such as alcohol and fatty acids, bile and 
Asparaginase markedly reduce glucose metabolism in PACs leading to reduced ATP 
synthesis and therefore substantial ATP loss. The combination of cytosolic Ca2+ overload 
and ATP depletion leads to profound cellular necrosis that could be avoided by ATP 
supplementation (22).  
We have now shown that the addition of pyruvate or galactose rescues cells from injury 
induced by all the principal agents inducing AP. Removal of glucose from the medium does 
not significantly affect the ATP loss and necrosis induced by these agents, indicating that 
glucose metabolism is severely inhibited. Phloretin, the glucose transport inhibitor (39) also 
completely blocked the galactose rescue effect (SFig.1C). Glucose and galactose are known 
to enter the cells by the same transporters (40), but galactose is converted to glucose-6-
phosphate by several enzymes without involving hexokinases (41,42). We therefore 
conclude that hexokinase inhibition is likely to play an important role in the ATP depletion 
that is a significant element in the development of AP.  
Our in vitro experiments (Fig.6) suggest that both alcohol metabolites and bile acids directly 
affect hexokinase enzymes, hexokinase 1 and 4 respectively, whereas the Asparaginase 
effect is indirect (18). The direct inhibition of hexokinases reduces but does not abolish ATP 
production (SFig.6A-C), as there can still be some production by a number of metabolic 
pathways. However, cellular ATP is severely depleted and at the same time cells are 
overstimulated by pathological substances, making recovery virtually impossible. Galactose 
addition in vivo (as well as pyruvate in vitro) rescues the cells from ATP depletion and hence 
necrosis. 
A relatively high dose (100 nM) of insulin reduced all POA- (26), BA- and Asparaginase-
induced necrosis (SFig.1D), most likely by potentiating hexokinases (28,29). An increased 
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glucose concentration (30 mM) potentiates glucokinase which has a low affinity for glucose 
(29) and also reduced both POA- and Asparaginase-induced necrosis (SFig.1D). However, 
such an increased glucose level failed to rescue BA-induced necrosis (SFig.1D). This is in 
line with our data regarding the inhibition of glucokinase by BA (Fig.6C), whereas both POA 
and Asparaginase have striking similarities in their pathological mechanisms, likely inhibiting 
hexokinase 1 (Fig.6A). Although both insulin and high glucose levels were effective in vitro, 
none of them could of course be employed in vivo. In contrast, galactose feeding, which 
appears to have no negative side-effects would be a potentially valuable therapy against AP.  
Galactose could also be used preventively, which could be of particular importance in cases 
where there is a significantly enhanced risk of AP (43), for example when treating ALL with 
Asparaginase. Our results indicate that galactose would be a valuable addition to the current 
Asparaginase treatment protocol. Substitution of drinking water in mouse models with a 10 
mM galactose solution significantly reduced all pathological scores in both Asparaginase- 
and alcohol metabolites-induced AP. Since this approach has been successful in treating 
experimental AP in the mouse, induced by several different agents, and relies on increasing 
the intracellular ATP/prevention of depletion of ATP, it might become useful also for treating 
other diseases with ATP loss and subsequent necrosis as well as counteracting similar side 
effects of other drugs. 
With regards to the clinical treatment of patients with AP, there is currently a debate about 
high versus low energy administration in the early phase of acute pancreatitis (44). The 
protocol for a current multi-centre randomised double-blind clinical trial only deals with the 
question of the potential merit of high-energy enteral tube feed versus zero-energy enteral 
tube feed (44). Our new results now suggest a need for clinical trials potentially using 
galactose instead of glucose in enteral tube feeds for patients in the early phase of AP.  
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Materials and methods 
Chemicals and reagents 
 
Fluorescent dyes – Fluo-4-AM, MgGreen-AM and propidium iodide (PI) were purchased 
from Thermo Fisher Scientific (UK). Collagenase was obtained from Worthington (Lorne, 
UK), Asparaginase was purchased from Abcam (UK), palmitoleic acid ethyl ester (POAEE) 
was from Cayman Chemical (UK). All other chemicals were purchased from Sigma (UK). 
C57BL/6 J mice were obtained from Jackson Laboratory (Charles River, UK).  
Antibodies 
Primary antibodies: Anti-HK1 (ThermoFisher Scientific) mouse monoclonal antibody (7A7) 
(MA5-15675) 1/500; Anti-HK2 (Abcam) mouse monoclonal antibody [1E8-H3-F11] ab131196 
1/500; Anti-HK4 (GCK) (ThermoFisher Scientific) rabbit polyclonal antibody (PA5-15072) 
1/500; Anti-b-actin (Santa Cruz Biotechnology) mouse polyclonal antibody (sc-47778) 1/500. 
Secondary antibodies: Pierce Goat anti-rabbit IgG, (H+L) peroxidase conjugated antibody 
(ThermoFisher Scientific) 31460 1/5,000; Goat anti-mouse IgG-HRP (Santa Cruz 
Biotechnology) sc-2005 1/1000. 
Isolation of PACs 
 
Cells were isolated as previously described (18). Briefly, animals were sacrificed according to 
the Animal Scientific Procedures Act, 1986 and approved by the Ethical Review Committee of 
Cardiff University. After dissection, the pancreas was digested using collagenase-containing 
solution (200 IU/ml, Worthington, UK) and incubated in a 37°C water bath for 14–15 min. The 
extracellular solution contained: 140 mM NaCl, 4.7 mM KCl, 10 mM Hepes, 1 mM MgCl2, 10 
mM glucose, pH 7.3, and CaCl2 1 mM and osmolarity checked by Osmomat 030. All in vitro 
experiments have been conducted using this solution, unless otherwise stated. 
 
Fluorescence measurements 
 
For measurements of [Ca2+]i, isolated PACs were loaded with Fluo-4-AM (5 M; excitation 488 
nm; emission 510-560 nm) following the manufacturer’s instruction. Measurement of 
intracellular ATP was performed with MgGreen, which senses changes in [Mg2+]i at 
concentrations around the resting [Mg2+]i (18). PACs were incubated with 4 M MgGreen AM 
for 30 min at room temperature (excitation 488 nm; emission 510-560 nm). ATP depletion 
mixture (4 µM CCCP, 10 µM oligomycin and 2 mM iodoacetate) was applied for a final 10 min 
of each experiment to induce maximum ATP depletion (21). Asparaginase was used in 
concentration of 200 IU/ml, POAEE 500 M (from the stock solution in ethanol, Cayman 
Chemicals UK), POA 30 M (from 30 mM stock in ethanol) and Sodium Choleate (BA) 0.06% 
unless stated otherwise. 
Necrotic cell death was assessed with propidium iodide (PI) uptake as previously described 
(excitation 535 nm; emission 617 nm) (4). The total number of cells showing PI uptake was 
counted in ≥3 series of experiments for each treated group (>100 cells per each sample) to 
provide a percentage as the mean ± SEM. 
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All experiments were performed at room temperature using freshly isolated cells attached to 
coverslips of the perfusion chamber. Fluorescence was imaged over time using Leica SP5 
two-photon, Leica TCS SPE and Zeiss spin-disk confocal microscopes.  
 
In vivo models of Asparaginase- and fatty acid ethyl ester-induced AP 
  
All animal studies were ethically reviewed and conducted according to UK Animals (Scientific 
Procedures) Act of 1986, approved by the UK Home Office. The animal procedures and 
experimental protocols were approved by Animal Care and Ethics Committees at Cardiff 
School of Biosciences, Cardiff University. Before and throughout the experiment unless 
otherwise denoted, mice were maintained in plastic cages with corn cob bedding; tap water 
and commercial pelleted diet were freely provided. To establish Asparaginase-induced AP, 
C57BL6/J mice received four daily (24 hours apart) intraperitoneal (IP) injections of 
Asparaginase in phosphate-buffered saline (PBS) at 20 IU/g. Control mice only received PBS 
IP injection. Treatment groups were defined as follows: galactose (180 mg/kg/day) fed (in 
drinking water 24 hours before the first Asparaginase IP and all the following days during 
injections) followed by Asparaginase injection (20 IU/g) or galactose (180 mg/kg/day) fed with 
galactose (180 mg/kg/day) and Asparaginase (20 IU/g) IP (n = 5-8 mice/group). Mice were 
sacrificed 96 hours after first injection and pancreas was extracted for histology or isolation of 
PACs. Blood was also collected for amylase and IL6 measurements. 
In FAEE-induced AP (FAEE-AP) group, mice received two intraperitoneal injections of ethanol 
(1.35 g/kg) and POA (150 mg/kg) at 1 h intervals as previously described (37). The treatment 
group animals were fed with galactose (180 mg/kg/day) as described previously. Animals were 
sacrificed at 24 hours after the final injection. 
 
Histology 
 
Pancreatic tissue was fixed in 4% formaldehyde, embedded in paraffin, and histological 
assessment was performed after H&E staining of fixed pancreatic slices (4 µm thickness). 
Evaluation was performed on ≥10 random fields (magnification: x200) by 2 blinded 
independent investigators grading (scale, 0–3) edema, inflammatory cell infiltration, and acinar 
necrosis as previously described (38), calculating the means ± SEM (n = 3-5 mice/group).  
 
Hexokinase activity 
 
To assay inhibitory effects of POA and BA on activity of hexokinase 1 (HK1), hexokinase 2 
(HK2) (Novus Biological) and hexokinase 4 (HK4) (Enzo Life Sciences), NADH generated by 
glucose-6-phosphate dehydrogenase was detected at 340nm as described in manufacturers’ 
protocols for the Hexokinase assay kit (MAK091, Sigma, UK). 
 
Western Blotting  
 
Equal amounts of proteins were resolved by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (4-12% SDS Bis Tris gels, ThermoFisher Scientific) and blotted; membranes 
were probed with primary and then secondary antibodies.  
Measurements of mitochondrial membrane potential (Δψm )  
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For measurements of mitochondrial membrane potential (Δψm) in PACs, we have used the 
dequench mode as previously described (25). Freshly isolated pancreatic cells were loaded 
with 20 µM TMRM for 25 min at room temperature. Cells were then washed and re-
suspended in extracellular solution. Fluorescence was excited by a 535 nm argon laser line, 
and emission was collected above 560 nm. All experiments were conducted by using a Leica 
TCS SPE confocal microscope with a 63x oil immersion objective. The region of interest for 
analysing the change of mitochondrial membrane potential was the whole cell. 
Measurements of mitochondrial Ca2+  
For mitochondrial calcium [Ca2+]m measurements (45), freshly isolated PACs were loaded 
with 10 µM Rhod-2-AM for 48 min at 30°C. After incubation the cells were centrifuged for 1 
min and re-suspended in extracellular solution. The fluorescence of Rhod-2 was excited 
using 535 nm laser line and the emitted light was collected above 560nm. 
Enzyme activity and Interleukin 6 measurements. 
Serum amylase was determined by spectrophotometer measurements at 405 nm (Jenway, 
Geneflow, UK) using Amylase Activity Assay Kit (MAK009, Sigma UK) according to 
manufacturer’s instructions. 
For visualization of trypsin activity, pancreatic acinar cells were incubated in extracellular 
solution containing 10 µM rhodamine 110, bis-(CBZ-L-isoleucyl-L-prolyl-L-arginine amide) 
dihydrochloride (BZiPAR) (Molecular Probes) (4), according to manufacturer’s instructions. 
BZiPAR were excited with a 488-nm laser line; emission was collected at 508-530-nm. 
Interleukin 6 (IL6) was determined by enzyme-linked immunosorbent assay (Abcam, UK). 
ATP measurements. 
Isolated PACs have been incubated during 2 hours with either POA, BA or Asparaginase 
with appropriate controls. Cellular ATP was determined in the homogenised cell preparation 
using ATP Essay kit (Sigma UK), according to manufacturer’s instructions.  
Statistical analysis 
 
Data were presented as mean ± SEM. Statistical significance and p-values were calculated 
using Student’s 2-tailed t-test or ANOVA, with *p < 0.05 and **p < 0.01 considered statistically 
significant and ***p < 0.001 was considered as highly significant.  
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Footnotes 
 
 Abbreviations used: 
AP   acute pancreatitis 
ALL   acute lymphoblastic leukaemia  
AAP   L-Asparaginase-induced acute pancreatitis 
ASNase L-Asparaginase 
CRAC   calcium release activated calcium channels 
PAR2   protease activated receptor 
PAC  pancreatic acinar cell 
PMCA   plasma membrane Ca2+ ATPase 
SERCA  sarco-endoplasmic reticulum Ca2+ ATPase  
POA   palmitoleic acid 
POAEE  palmitoleic acid ethyl ester 
FAEE  fatty acid ethyl ester 
2-DG  2-Deoxy-D-glucose 
PI  propidium iodide 
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Figure. 1. Asparaginase (ASNase), non-oxidative alcohol metabolites (POAEE and POA) and bile 
acids (BA) all induce substantial ATP loss and cell necrosis. 
A. Comparison of cellular ATP depletion in PACs after treatments of cells for 30 min with or without 
glucose (0 G), or application of ASNase, POAEE, POA or BA. Level of ATP loss (measured by 
MgGreen) is shown as a percentage of full depletion by a mixture of CCCP, oligomycin and 
iodoacetate. Dots represent ATP loss (%) in each cell. Bars present mean ±SEM. 
B. Summary of cell necrosis measurements in PACs treated with ASNase, POA or BA for 2 hours in 
the presence or absence (0G) of 10 mM glucose as compared with control. Removal of glucose 
had little effect on ASNase and POA but increased BA-induced necrosis. Cells were stained with 
propidium iodide (PI). Dots represent series of experiments with n>100 cells in each sample. 
Bars present mean±SEM.  
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Figure 2. Pyruvate and galactose provide substantial protection against alcohol- and bile- induced ATP 
loss and necrosis in PACs.  
A. POAEE (500 M) – induced ATP depletion is markedly reduced by adding 1 mM galactose. 
Averaged traces with error bars (POAEE, n=8; Galactose + POAEE, n=11). 
B. ͚Area uŶder the Đurǀe͛ comparison of traces shown in A. Galactose reduced POAEE-induced ATP 
depletion (p<0.0001). 
C. POAEE-induced necrosis was significantly reduced by adding 1 mM galactose (p<0.003; 3 series of 
experiments with more than 100 cells in each sample).  
D. POA (50M) – induced ATP depletion is reduced by replacing glucose with 10 mM galactose. 
Averaged traces with error bars (POA, n=24; Galactose + POA, n=17). 
E. ͚Area uŶder the Đurǀe͛ comparison of traces shown in D. Galactose significantly reduced POA-
induced ATP depletion (p<0.0001). 
F. POA-induced necrosis was reduced significantly by replacing glucose with either 10 mM pyruvate 
or 10 mM galactose (p<0.0001 in both series; dots represents a series of experiments with >100 cells 
in each sample). 
G. Bile acid mixture (BA)-induced ATP depletion is reduced by adding 1mM pyruvate. Averaged 
traces with error bars (BA, n=8, BA+ pyruvate n=6). 
H. Area under the curve comparison of traces shown in G. Pyruvate significantly reduces BA-induced 
ATP depletion (p<0.002). 
I. BA-induced necrosis is reduced to nearly control level by replacing glucose with 10 mM pyruvate 
(p<0.00015; 5 series of experiments with more than 100 cells in each sample) or 10 mM galactose 
(p<0.008; 4 series of experiments with more than 100 cells in each sample). 
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Figure 3. Pyruvate and galactose significantly reduce the level of Asparaginase-induced necrosis. 
A. Representative images of cells from experiments shown in B and C. 
B. In PACs, 1 mM pyruvate (5.4+0.5%, three series with n > 300, p < 0.0002) or 1 mM galactose (6.5 ± 
0.7%, three series with n > 300, p < 0.0004) reduce the ASNase -induced necrosis level as compared 
to ASNase alone (17.5 ± 0.4%, six series with n > 300). 
C. Complete replacement of extracellular glucose (10 mM) with pyruvate (10 mM) (5.6 ± 0.6%, three 
series with n > 300, p < 0.0001) or 10 mM galactose (7.1 ± 1.1%, three series with n > 300, p < 0.001) 
reduces significantly the ASNase-induced necrosis level as compared to the control level (3.8 ± 0.6%, 
three series with n > 300).  
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Figure 4. Asparaginase-induced Ca2+ overload and ATP loss were substantially reduced by 
galactose or pyruvate, whereas glucose removal did not affect the ATP loss.  
A. ASNase elicits an elevated [Ca2+]i plateau with repetitive Ca2+ transients on top, averaged traces 
with error bars shown (red, n = 35). Green trace shows reduced response to ASNase in the presence 
of 1 mM pyruvate (after 5 min of preincubation, n = 33). Purple trace shows reduced response to 
ASNase in the presence of 1 mM galactose (after 15min of preincubation, n=17). 
B. Comparison of the ͚areas under the curve͛ shown in A during first 30min of the [Ca2+]i change in 
response to ASNase in the presence of pyruvate (green) and galactose (purple) or asparaginase 
alone (red) (p<0.0001). Both pyruvate and galactose reduced significantly the [Ca2+]i rise induced by 
ASNase. 
C. ATP loss was evaluated using MgGreen. Average traces show that complete replacement of 
extracellular glucose (10 mM) with pyruvate (10 mM) (green, n = 19) or galactose (10 mM) (purple, n 
= 16) for 30 min markedly reduces [Mg2+]i change induced by ASNase (red, n = 38).  
D. Quantitative analysis of experiments of the type shown in C (area under the curve during the 30 
min of ASNase application). Pyruvate (green) and galactose (purple) markedly reduced the ATP loss 
evoked by ASNase (red, p < 0.0005).  
E. Quantitative analysis of experiments like in C but with 1mM of either pyruvate (green, n=14) or 
galactose (purple, n=16) added before the application of ASNase. Bars show the ͚area under the 
curve͛ recorded during 30 min of ASNase application. Both treatments reduced significantly the ATP 
loss ;͚area uŶder the Đurǀe͛Ϳ (p < 0.015).  
F. ASNase induces substantial ATP loss in the absence of pyruvate irrespective of whether 
extracellular glucose was present (red, n = 21) or absent (orange, n = 17). In contrast, adding 
pyruvate (1 mM) dramatically decreased ATP depletion induced by ASNase irrespective of the 
absence (green trace, n = 16) or presence of 10 mM glucose (blue trace, n = 14). 
G. Quantitative analysis of experiments shown in F by comparing ͚areas uŶder the Đurǀe͛ during 30 
min of ASNase application. Pyruvate (blue and green) was highly protective against ATP depletion 
induced by ASNase, (p < 0.0001) regardless of presence or absence of glucose (p>0.05). 
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H. Comparison of amplitudes of traces at 2000 sec shown in F. Pyruvate (blue and green) is highly 
effective against cellular ATP depletion induced by ASNase, p < 0.0001 regardless of presence (red) 
or absence of glucose (orange). 
 
Figure 5. Pyruvate and galactose increase intracellular ATP levels and protect cells against ATP 
depletion induced by 2-deoxyglucose (2-DG). 
A. Glucose removal induces substantial ATP depletion, whereas pyruvate or galactose boosts ATP 
production. Average traces show normalized changes of MgGreen fluorescence in PACs in the 
presence (blue trace, n = 8) or absence (orange trace, n = 7) of 10 mM glucose or in the presence 
of pyruvate (1 mM; green trace, n = 10) or galactose (1 mM; purple trace, n = 8). 
B. Comparison of ͚areas under the curve͛ for experiments shown in A.  
C. Pyruvate markedly reduces ATP depletion induced by 10 mM 2-Deoxy-D-glucose (2-DG). 
Averaged trace (shown with error bars) represents the result of application of 2-DG in the absence 
(red trace, n = 9) or presence of 1 mM pyruvate (after 5 min pre-incubation, green trace, n=7).  
D. Comparison of necrotic cell death levels induced by 2 hours incubation of PACs with 10 mM 2-DG 
or ASNase with control (non-treated cells) (PI stained cells, p = 0.36, three series of experiments 
with n>100 cells in each sample). 
E. Average traces show normalized changes of Fluo-4 fluorescence in PACs induced by 10 mM 2-DG 
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alone (red trace, n=10) or after 5 min pre-incubation of cells and continuous presence of 1mM 
pyruvate (green trace, n = 8) for 25 min. 
F. QuaŶtitatiǀe aŶalǇsis of eǆperiŵeŶts of the tǇpe shoǁŶ iŶ E ďǇ ĐoŵpariŶg ͚areas uŶder the Đurǀe͛ 
for 25 min of the recording after application of 10 mM 2-DG (p < 0.001). 
 
Figure 6. Hexokinase activity is significantly inhibited in vitro by POA and BA. 
A. Hexokinase 1 activity (HK1) is reduced significantly by 0.1mM POA (n=6, P<0.0001,) but not 
changed significantly by 0.05% BA (n=4, p>0.13) as compared with control (n=6). 
B. Hexokinase 2 activity (HK2) is reduced significantly by 0.1mM POA (n=9, p<0.0001,) but not 
affected by 0.05% BA (n=4, p>0.3) as compared to control (n=13). 
C. Hexokinase 4 activity (HK4) is reduced significantly by 0.05% BA (n=8, p<0.0001,) but not 
affected by 0.1mM POA (n=4, p>0.8) as compared to control (n=6). 
D. Western blot analysis of the expression levels of HK1, HK2 and HK4 in PACs (representative 
case, repeated 3 times with similar results). 
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Figure 7. Galactose protects against alcohol-induced acute pancreatitis in vivo. 
A. Galactose improved significantly the pathological scores in FAEE-AP. Representative H&E images 
of pancreas histology slides showing normal pancreatic histology (saline injection), typical 
histopathology from FAEE-AP without or with galactose (Gal) feeding (10 mM). Lower row of images 
shows zoomed parts of the images above (H&E; scale bar: 50 µm). 
B-E. Overall histopathological score (E) and components: edema (B), inflammation (C) and necrosis 
(D). All detrimental changes induced by POA and ethanol were significantly ameliorated by galactose 
(p <0.007). Values are means ± SE of 3-5 mice per group). 
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Figure 8. Asparaginase-induced acute pancreatitis is substantially reduced by galactose in vivo. 
A. Representative H&E images of pancreas from slides showing normal pancreatic histology (saline), 
typical histopathology from AAP model (ASNase 20 IU/g), and typical histopathology from treatment 
groups: galactose feeding (Gal F) and combination of galactose feeding and galactose injection (Gal 
FI). Lower row of images shows zoomed parts of the images above (H&E; scale bar: 50 µm). 
B-E. Edema (B), inflammation (C), necrosis (D) and overall histopathological score (E) in ASNase-
induced AP and the effects of the two different galactose treatment protocols (180mg/kg/day of 
galactose in each protocol). All detrimental changes induced by ASNase were significantly 
ameliorated by galactose (p < 0.004, values are means ± SE of 3-5 mice per group). 
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Supplemental figures.
 
Supplemental Figure 1. Asparaginase induced reduction in NADH and increase in FAD in PACs as 
opposed to ACh. Phloretin inhibits both glucose and galactose transport. 30 mM glucose rescues 
only Asparaginase- and POA-induced necrosis, whereas 100 nM insulin rescued the necrosis 
induced by all three agents, Asparaginase, POA and BA. 
A. Average traces represent simultaneous measurements of cytosolic NADH and FAD in PACs during 
application of 200 IU/ml ASNase. Bars present mean±SEM (n=8).  
B. Average traces represent simultaneous measurements of cytosolic NADH and FAD in PACs  during 
application of 100 nM ACh. Bars present mean±SEM (n=8).  
C. Comparison of necrotic cell death levels induced by 2 hours incubation of PACs with 200 IU/ml 
ASNase in the absence or presence of 1 mM Galactose or 1 mM phloretin (inhibitor of active glucose 
transport into cells) (PI stained cells, p = 0.36, three series of experiments with n>100 cells in each 
sample). 
D. Comparison of ASNase- POA- and BA-induced necrosis in different conditions: increased glucose 
(30mM) and in the presence of insulin (100nM). Increased glucose (30 mM) on its own did not 
change the control level of necrosis (p>0.4), but reduced significantly the level of necrosis induced by 
ASNase and POA (p<0.0001). In contrast, 30 mM glucose did not change the level of necrosis induced 
by BA (p>0.8). 100nM of insulin reduced significantly the level of necrosis induced by ASNase 
(p<0.0001), POA-(p<0.0001) and BA (p<0.001) (PI stained cells, dots represent series of experiments 
with n>100 cells in each sample). 
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Supplemental Figure 2. Asparaginase-induced mitochondrial depolarisation is 
rescued by pyruvate or galactose. 
A. TMRM fluorescence and transmitted light image of the cell cluster. (Scale bar: 10 µm) 
B. Measurements of the mitochondrial membrane potential were performed using the 
fluorescence probes TMRM. The effect of ASNase (200 IU/ml)-induced loss of ΔψM 
followed by 5 nM CCCP on mitochondrial membrane potential in pancreatic acinar cells 
loaded with 10 µM TMRM (dequench mode, n = 33). 
C. The trace shows normalized fluorescence changes induced by ASNase (200 IU/ml) in 
pancreatic acinar cells within 30 min (n = 33). 
D. The ASNase effect was markedly reduced by 5 min incubation of 1mM pyruvate in 
pancreatic acinar cells (n = 12). 
E. The ASNase effect was also markedly reduced by 15 min incubation 1mM galactose in 
pancreatic acinar cells (n = 12). 
F. Comparisons of the integrated responses show that pyruvate and galactose significantly 
reduced the ASNase-induced mitochondrial depolarization (p < 0.001 for both treatments). 
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Supplemental Figure 3. Asparaginase-induced mitochondrial calcium overload is 
rescued by pyruvate or galactose. 
A. Rhod-2 fluorescence and transmitted light image of doublet of pancreatic acinar cells. 
(Scale bar: 10 µm) 
B. Measurements of the mitochondrial calcium were performed using the fluorescence 
probes Rhod-2-AM. The trace shows effects of ASNase (200 IU/ml) followed by 1 µM 
ACh on mitochondrial calcium (n = 14). 
C. The trace shows effect of ASNase (200 IU/ml) on mitochondrial calcium response 
significant is decreased by 5 min preincubation of 1 mM pyruvate in pancreatic acinar 
cells (n = 17). 
D. The trace shows effect of ASNase (200 IU/ml) on mitochondrial calcium response 
significant is decreased by 15 min preincubation of 1 mM galactose in pancreatic acinar 
cells (n = 6). 
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E. The trace shows mitochondrial calcium response by 1 µM ACh (n = 7). 
F. Quantitative analysis of experiments of the type shown in B-D by comparing the 
integrated mitochondrial calcium change above the baseline (area under the curve) 
recorded during the first 1000 sec of ASNase application (p < 0.001 for both treatments). 
 
Supplemental Figure 4. Galactose but not glucose feeding has rescued blood 
amylase levels and IL6 in the alcohol-induced AP model. 
 
A. Plasma amylase levels have been substantially elevated in alcohol-induced AP model 
(p<0.0001, n=5). Galactose feeding has reduced amylase levels to nearly control 
levels (p>0.5, n=8). Glucose feeding (180mg/kg/day) did not significantly change 
amylase levels (p>0.5, n=4). 
B. Plasma IL6 levels have been substantially increased in alcohol-induced AP model 
(p<0.0001, n=4). Galactose feeding has reduced IL6 levels to nearly control levels 
(p>0.9, n=6). Glucose feeding has partially reduced elevated IL6 levels (p<0.006, 
n=6). 
C. Weight loss typical for the AP model (p<0.0001, n=26) has been partially reduced by 
galactose feeding (p<0.006, n=23). Glucose feeding did  not significantly change 
weight loss (p>0.9, n=5). 
D. Weight loss induced by Asparaginase model of AP (p<0.0001, n=8) has been partially 
reduced by galactose (p<0.01, n=9). 
E. Drink consumption has been reduced in alcohol-induced AP model (p<0.0007, n=5). 
Galactose feeding has not significantly change reduced drink consumption (p>0.6, 
n=6). 
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Supplemental Figure 5. Intracellular trypsin activation induced by Asparaginase, POA 
or BA has been substantially reduced by galactose. 
A. ASNase (200 IU/ml) – evoked trypsin activation was reduced by 10 mM galactose. 
Averaged traces with error bars (ASNase, n=12; ASNase + Galactose, n=15).  
B. ‘Area under the curve’ comparison of traces shown in A. Galactose significantly 
reduced ASNase- evoked trypsin activation (p<0.0001). 
C. POA (50µM) –evoked trypsin activation was substantially reduced by 10 mM 
galactose. Averaged traces with error bars (POA, n=16; POA + Galactose, n=25).  
D. ‘Area under the curve’ comparison of traces shown in C. Galactose markedly reduced 
POA-induced ATP depletion (p<0.0001). 
E. BA (0.06%) –evoked trypsin activation is reduced by 10 mM galactose. Averaged 
traces with error bars (BA, n=12; BA + Galactose, n=22).  
F. ‘Area under the curve’ comparison of traces shown in E. Galactose markedly reduced 
POA-induced ATP depletion (p<0.0001). 
 29 
 
G. Averaged trace shows BZiPAR fluorescence of non-stimulated control in pancreatic 
acinar cells (n=17).  
H. Averaged trace shows BZiPAR fluorescence of 10 mM galactose treatment in 
pancreatic acinar cells (n=18). 
 
 
Supplemental Figure 6. 
Galactose partially rescues ATP depletion in cells treated with either POA or 
BA or Asparaginase. 
A. POA treatment (2 hours) induced a substantial ATP loss in PACs (p<0.0001, n=4). 
Galactose substantially reduced ATP loss (p<0.0001, n=4). 
B. BA treatment of PACs induced a substantial ATP loss (p<0.0001, n=4). Galactose 
substantially reduced ATP loss (p<0.0022, n=4). 
C. Asparaginase treatment of PACs induced a substantial ATP loss (p<0.0001, n=4). 
Galactose substantially reduced ATP loss (p<0.0006, n=4). 
 
